NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE
Post# of 341
(Total Views: 174)
Posted On: 08/27/2021 4:25:01 PM
NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Eyes Fueled Mission to Develop Revolutionary Psychedelic Therapeutics
Cybin (NEO: CYBN) (NYSE American: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, in a recent historic move became the first psychedelic biotech company to trade on the NYSE American LLC stock exchange. “We are all delighted to receive this approval from the NYSE American and are thankful to our wonderful team and loyal investor base who have followed us on this journey so far,” an article quoted Cybin CEO Doug Drysdale discussing the milestone. “As the first psychedelic biotech company that will now trade on this esteemed exchange in the U.S., we will commit resources to reach the broadest investor audience with our mission and will continue to accelerate our efforts to position Cybin as a leader in the sector.” Drysdale noted that expanded access to investors is expected to further fuel Cybin’s mission to develop revolutionary psychedelic therapeutics for patients suffering from mental health conditions.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Cybin (NEO: CYBN) (NYSE American: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, in a recent historic move became the first psychedelic biotech company to trade on the NYSE American LLC stock exchange. “We are all delighted to receive this approval from the NYSE American and are thankful to our wonderful team and loyal investor base who have followed us on this journey so far,” an article quoted Cybin CEO Doug Drysdale discussing the milestone. “As the first psychedelic biotech company that will now trade on this esteemed exchange in the U.S., we will commit resources to reach the broadest investor audience with our mission and will continue to accelerate our efforts to position Cybin as a leader in the sector.” Drysdale noted that expanded access to investors is expected to further fuel Cybin’s mission to develop revolutionary psychedelic therapeutics for patients suffering from mental health conditions.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)